Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
Portfolio Pulse from
Valneva has received a positive opinion from the EMA's CHMP for extending the label of its chikungunya vaccine, IXCHIQ®, to include adolescents aged 12 and older. If approved, it will be the first vaccine for chikungunya available in the EU for this age group.
February 28, 2025 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva's chikungunya vaccine IXCHIQ® has received a positive opinion from the EMA's CHMP for use in adolescents. This could lead to the first EU-approved chikungunya vaccine for ages 12 and up.
The positive CHMP opinion is a significant regulatory step towards approval, potentially expanding the market for Valneva's vaccine. This could lead to increased revenues and market presence in the EU, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100